Literature DB >> 21934500

Acquired immune and inflammatory myopathies: pathologic classification.

Alan Pestronk1.   

Abstract

PURPOSE OF REVIEW: We discuss pathology-based characterization and classification of acquired immune and inflammatory myopathies (IIMs). RECENT
FINDINGS: Several types of IIMs do not fit well into the typical IIM subclassifications: dermatomyositis, polymyositis and inclusion body myositis (IBM). Myopathologic features that can provide additional diagnostic clarification in IIM are types of muscle fiber pathology; immune changes (cellular and humoral); and tissues with distinctive involvement (connective tissue, vessels and muscle fibers). Pathologic classification categories include immune myopathies with perimysial pathology (IMPP), a group that can be associated with antisynthetase antibodies; myovasculopathies, including childhood dermatomyositis; immune polymyopathies, active myopathies with little inflammation such as the myopathy with signal recognition particle antibodies; immune myopathies with endomysial pathology (IM-EP), illustrated by brachio-cervical inflammatory myopathy (BCIM); histiocytic inflammatory myopathies, like sarcoid myopathy; and inflammatory myopathies with vacuoles, aggregates and mitochondrial pathology (IM-VAMP), which have inclusion body myositis as a pathologic subtype and are poorly treatable. Some myopathologic features, like B-cell foci and alkaline phosphatase staining of capillaries or perimysium, are more likely to be present in treatable categories of IIM.
SUMMARY: Myopathology can be used to classify IIM. Identification of distinctive myopathologic changes in IIM can improve diagnostic and prognostic accuracy and focus treatment, therapeutic trials and studies of pathogenic factors.

Entities:  

Mesh:

Year:  2011        PMID: 21934500     DOI: 10.1097/BOR.0b013e32834bab42

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  32 in total

Review 1.  Myogenesis and muscle regeneration.

Authors:  Faisal Yusuf; Beate Brand-Saberi
Journal:  Histochem Cell Biol       Date:  2012-05-27       Impact factor: 4.304

2.  Fatal cardiac involvement complicating antisynthetase syndrome.

Authors:  Stefen Brady; Sunil Melath; Renata S Scalco; Henry Penn
Journal:  BMJ Case Rep       Date:  2014-08-25

Review 3.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

4.  Immune myopathy with large histiocyte-related myofiber necrosis.

Authors:  Alan Pestronk; Namita Sinha; Ziad Alhumayyd; Cindy Ly; Robert Schmidt; Robert Bucelli
Journal:  Neurology       Date:  2019-03-20       Impact factor: 9.910

5.  Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy.

Authors:  Bruna Cerbelli; Annalinda Pisano; Serena Colafrancesco; Maria Gemma Pignataro; Marco Biffoni; Silvia Berni; Antonia De Luca; Valeria Riccieri; Roberta Priori; Guido Valesini; Giulia d'Amati; Carla Giordano
Journal:  Virchows Arch       Date:  2017-11-16       Impact factor: 4.064

6.  Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies.

Authors:  Jean Marcos de Souza; Leonardo Santos Hoff; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2019-02-18       Impact factor: 2.631

7.  Estrogen Downregulates miR-21 Expression and Induces Inflammatory Infiltration of Macrophages in Polymyositis: Role of CXCL10.

Authors:  Wang Yan; Caijing Chen; Huimin Chen
Journal:  Mol Neurobiol       Date:  2016-02-12       Impact factor: 5.590

Review 8.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

9.  Clinico-serologic features of statin-induced necrotising autoimmune myopathy in a single-centre cohort.

Authors:  Michael J Waters; Vidya Limaye
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 10.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.